Recent developments include closing over $10 million in financing, expanding manufacturing partnerships, Nasdaq compliance issues, and operational updates.

• Celularity closed over $10 million in initial financing in September 2026 and targets positive operating cash flow by Q1 2027 [N1].
• The company expanded cellular medicine manufacturing capabilities through a partnership with MuseCell Innovations announced in August 2026 [N3][N4].
• Celularity faced Nasdaq compliance issues related to delayed 10-Q filings in August 2026 and is working to regain compliance [N5].
• Biovance and Biovance 3L products remain eligible for medical coverage under withdrawn Local Coverage Determinations as of December 2025 [N7].
• Celularity has partnered with Fountain Life to provide stem cell therapies following new Florida legislation authorizing such treatments [N8].

Celularity’s cellular therapy candidates, including cenplacel-L and NK cell programs, represent innovative approaches to modulating biological processes associated with aging and degenerative diseases. The company’s manufacturing capabilities and partnerships enhance its ability to scale production and generate revenue from third-party services. Recent financing provides capital to support operational needs and development activities. The company’s efforts to regain Nasdaq compliance and improve financial performance, including targeting positive operating cash flow by Q1 2027, indicate progress in addressing prior challenges. Continued advancements in clinical programs and regulatory clarity could enhance Celularity’s commercial prospects and market positioning.

Celularity faces significant liquidity constraints with a working capital deficit and minimal cash reserves as of March 31, 2026, raising substantial doubt about its ability to continue as a going concern. The company has experienced steep declines in product sales due to reimbursement uncertainties and changes in customer purchasing behavior. Nasdaq compliance issues related to delayed filings and minimum bid price requirements pose risks to continued listing. The investigational status of its cellular therapy candidates means safety and efficacy are not established, and regulatory approvals remain uncertain. Dependence on additional financing and successful execution of strategic realignment are critical, with no assurance of achieving sustainable profitability or operational stability.

Celularity’s moat is based on its proprietary cellular therapy platform utilizing placenta-derived cells, a scalable and biologically unique source for allogeneic therapies. The company’s integrated manufacturing infrastructure and biobanking services provide operational capabilities that support both internal development and third-party service offerings. Strategic partnerships and licensing arrangements, such as the transaction with NexGel and collaborations with MuseCell Innovations, extend Celularity’s reach in biomaterials commercialization and manufacturing. The company’s focus on longevity and age-related diseases targets a specialized niche with scientific and clinical complexity, which may present barriers to entry for competitors. However, the investigational nature of its therapies and regulatory uncertainties pose ongoing challenges to establishing a durable competitive advantage.

• Liquidity and Going Concern Risk: Celularity has minimal cash and a working capital deficit as of March 31, 2026, with substantial doubt about its ability to continue as a going concern without additional financing [S2].
• Regulatory and Reimbursement Uncertainty: Delays and ambiguity in Medicare coverage guidance for biomaterial products have negatively impacted product sales and customer purchasing behavior [S2].
• Nasdaq Compliance Risk: The company has faced Nasdaq notices for delayed 10-Q filings and failure to maintain minimum bid price, risking potential delisting [N5][S2].
• Clinical and Development Risk: Celularity’s cellular therapy candidates are investigational with unestablished safety and efficacy, subject to regulatory approval and clinical trial outcomes [S2].
• Execution Risk: Successful implementation of business realignment, partnerships, and manufacturing expansion depends on execution, counterparty performance, and market demand [S2][N3][N4].